Prognostic significance of ischemia modified albumin after percutaneous coronary intervention

Dušek, J; Šťásek, Josef; Tichý, M.; Bis, Josef; Gregor, J; Vojáček, Jan; Mašín, Vladimír; Polanský, Pavel; Brtko, Miroslav; Cernohorský, D

doi:10.1016/j.cca.2005.11.020

Cited by 28 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ischemia-modified albumin (IMA) is the variant form of human serum albumin of which N-terminal end has been altered after it was exposed to oxidative stress and/or ischemia [10,11]. Metal binding ability of N-terminal end is decreased after this molecular alteration [10,11]. In clinical and experimental studies conducted so far, it has been demonstrated that IMA elevates depending on oxidative stress after acute ischemia and returns to normal levels in hours after reperfusion [12][13][14][15].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin

Ükinç

Eminağaoğlu

Ersöz

et al. 2009

Endocr

View full text Add to dashboard Cite

Ischemia-modified albumin (IMA) is a novel marker of tissue ischemia. Nowadays, IMA is accepted as a marker of oxidative stress. In this study, we aimed at establishing an association between IMA and hyperglycemia, blood pressure, lipid parameters, microvascular complications, hsCRP, and microalbuminuria in type 2 diabetes patients without overt macrovascular disease and acute ischemia. Fifty type 2 diabetes mellitus patients without a history of macrovascular disease or end-stage renal disease were enrolled into the study. Age-matched 30 healthy individuals were also included in the study as a control group. Plasma IMA (0.329 ± 0.046 and 0.265 ± 0.045 AbsU; P < 0.0001) and hsCRP levels (0.51 ± 0.36 and 0.32 ± 0.17 mg/dl; P < 0.0001) were significantly higher in the diabetic group compared to healthy controls. IMA level was significantly correlated with hsCRP (r = 0.76; P < 0.0001), HbA1c (r = 0.72; P < 0.0001), microalbuminuria (r = 0.40; P = 0.004), systolic blood pressure (r = 0.28; P = 0.049), diastolic blood pressure (r = 0.44; P = 0.005), and HOMA-IR (r = 0.42; P = 0.005) levels in the entire diabetic subjects. In the diabetic patients group, presence of microalbuminuria was associated with a higher plasma IMA level (0.355 ± 0.035 and 0.265 ± 0.0045 AbsU; P < 0.0001, patients with microalbuminuria and control subjects, respectively). In the type 2 diabetes patients with nephropathy, IMA level (0.355 ± 0.035 and 0.311 ± 0.046 AbsU; P = 0.002) was determined higher compared to the diabetes patients without nephropathy. Diabetic patients without an overt cardiovascular disease still have a higher serum IMA level compared to healthy controls. The correlation of high plasma IMA levels with high hsCRP and microalbuminuria levels in diabetic subjects indicates the presence of a chronic ischemic process. Therefore, elevated IMA levels may indicate an underlying subclinical vascular disease in type 2 diabetes mellitus patients.

show abstract

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin

Ükinç

Eminağaoğlu

Ersöz

et al. 2009

Endocr

View full text Add to dashboard Cite

show abstract

“…Ischemia, through hypoxia, acidosis, free radical injury, and energy-dependent membrane disruption, may reduce the binding capacity of the amino terminus of albumin to bind metals, such as cobalt, copper, and nickel. IMA may even be associated to clinical outcome in both ACS and PCI (15,16).…”

Section: Introductionmentioning

confidence: 96%

Ischemia‐modified albumin in acute aortic dissection

Sbarouni

Γεωργιάδου

Marathias

et al. 2010

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Relative risk of events was higher in those with high Troponin (cTnT) and ischemia modified albumin (IMA) (21%) versus negative ischemia modifies albumin (IMA) plus troponin (cTnT) (1.5%) but neither ischemia modified albumin (IMA) nor troponin (cTnT) alone were predictive of events as in Peacock's meta-analysis. 11 Dusek et al 12 reported in 60 patients with stable angina pectoris who underwent elective percutaneous intervention (PCI) that a median follow up of 46 months, people with higher ischemia modified albumin (IMA) (>130 U/L) was found to be associated with higher target vessel revascularization rate in the univariate analysis though there were no death or myocardial infarctions noted. This shows ischemia modified albumin (IMA) may be a useful marker to predict further need of re-intervention after percutaneous intervention or revascularization (PCI).…”

Section: Methodsmentioning

confidence: 99%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

Aims and Objectives: To find out if ischemia modified albumin can be a novel marker in ischemic heart disease. Materials and methods: Retrospective chart-review of chest pain patients who were evaluated in the emergency departments in 2006 and 2007. Results: Total of 400 patients presented with chest pain and subsequently were evaluated in the Emergency department at two major emergency departments associated with the teaching hospital associated Mercy Catholic Medical Center; few patients were excluded due to unavailability of complete data and follow-up visit in next six months. Thus, finally 351 patients met criteria for final analysis. Primary endpoints included the cardiac events and secondary outcomes were course in the hospital, days of hospitalization, interventions done in the hospital, disposition from the hospital, and readmission within next six months. Sensitivity and specificity of ischemia modified albumin (IMA) test was 80% and 50% respectively and positive predictive value and negative predictive values were 17% and 88% respectively. There were no further differences in cardiac events or interventions in higher ischemia modified albumin (IMA) group as compared to troponin (cTnT) (p=0.5). People with higher ischemia modified albumin (IMA) showed longer hospitalization days (p=0.025), needing nursing home or skilled nursing facility on discharge due to high discharge needs (p=0.0001) and had more readmissions as compared to troponin (p=0.02). However, Higher ischemia modified albumin (IMA) did not predict more cardiovascular events during hospital stay, rather troponin (cTnT) test predicted arrhythmia more than ischemia modified albumin (IMA) test (p=0.0001). Conclusion: Ischemia-modified albumin may be utilized as a novel marker of ischemia to rule out acute coronary syndrome along with troponin and electrocardiogram in the emergency departments. This test may also have short and long-term prognostic significances and may even be used as a surrogate marker in stroke, sepsis and thrombo-embolic diseases once these people need admission to the hospital.

show abstract

Prognostic significance of ischemia modified albumin after percutaneous coronary intervention

Cited by 28 publications

References 12 publications

A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin

A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin

Ischemia‐modified albumin in acute aortic dissection

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Contact Info

Product

Resources

About